1. Home
  2. QTTB vs IZM Comparison

QTTB vs IZM Comparison

Compare QTTB & IZM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QTTB
  • IZM
  • Stock Information
  • Founded
  • QTTB 2015
  • IZM 2011
  • Country
  • QTTB United States
  • IZM China
  • Employees
  • QTTB N/A
  • IZM N/A
  • Industry
  • QTTB Biotechnology: Pharmaceutical Preparations
  • IZM Consumer Electronics/Video Chains
  • Sector
  • QTTB Health Care
  • IZM Consumer Discretionary
  • Exchange
  • QTTB Nasdaq
  • IZM Nasdaq
  • Market Cap
  • QTTB 19.0M
  • IZM 21.1M
  • IPO Year
  • QTTB N/A
  • IZM 2023
  • Fundamental
  • Price
  • QTTB $1.50
  • IZM $2.64
  • Analyst Decision
  • QTTB Hold
  • IZM
  • Analyst Count
  • QTTB 8
  • IZM 0
  • Target Price
  • QTTB $24.00
  • IZM N/A
  • AVG Volume (30 Days)
  • QTTB 142.2K
  • IZM 21.1K
  • Earning Date
  • QTTB 08-07-2025
  • IZM 06-20-2025
  • Dividend Yield
  • QTTB N/A
  • IZM N/A
  • EPS Growth
  • QTTB N/A
  • IZM N/A
  • EPS
  • QTTB N/A
  • IZM N/A
  • Revenue
  • QTTB N/A
  • IZM $180,553,977.00
  • Revenue This Year
  • QTTB N/A
  • IZM N/A
  • Revenue Next Year
  • QTTB N/A
  • IZM N/A
  • P/E Ratio
  • QTTB N/A
  • IZM N/A
  • Revenue Growth
  • QTTB N/A
  • IZM N/A
  • 52 Week Low
  • QTTB $1.38
  • IZM $1.18
  • 52 Week High
  • QTTB $53.79
  • IZM $3.19
  • Technical
  • Relative Strength Index (RSI)
  • QTTB 40.47
  • IZM 70.88
  • Support Level
  • QTTB $1.47
  • IZM $2.44
  • Resistance Level
  • QTTB $1.65
  • IZM $2.47
  • Average True Range (ATR)
  • QTTB 0.12
  • IZM 0.07
  • MACD
  • QTTB -0.02
  • IZM 0.00
  • Stochastic Oscillator
  • QTTB 15.69
  • IZM 100.00

About QTTB Q32 Bio Inc. Common Stock

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

About IZM ICZOOM Group Inc.

ICZOOM Group Inc is engaged in the sale of electronic component products to customers in China. These products are used by small and medium-sized enterprises (SMEs) in the consumer electronic industry, Internet of Things (IoT), automotive electronics, and industrial control segment. In addition to the sales of electronic component products, also provides services to customers such as temporary warehousing, logistic and shipping, and customs clearance and charges them additional service commission fees. The company earns maximum revenue from sale of electronic components.

Share on Social Networks: